.png)
U.S. Pharmaceutical Imports Might Soon Face Tariffs: 3 Stocks That Could Tumble as a Result
There's little doubt these pharmaceutical companies' costs will soon be rising at least a little.
The tariff war the U.S. is waging against most of the world stabilized somewhat earlier this month. But let's face facts -- it could easily flare up again. President Donald Trump appears quite committed to the idea of leveraging America's economic dominance, and no industry is immune to this dynamic.
One could argue, however, that the pharmaceutical industry is especially vulnerable. Although the 25% import tariff rate the White House has threatened on foreign-made drugs and drug components is neither sky-high nor a guaranteed figure (and may only be a means of forcing negotiations), this administration has voiced clear concerns about any American dependence on overseas suppliers of medicines.
Higher import tariffs could, in theory, encourage domestic drug companies to move more of their production here.
